Yesintek®
Understanding Yesintek™
Yesintek™ (satralizumab-mwge) is a monoclonal antibody developed to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-AQP4 antibody positive. It works by blocking interleukin-6 (IL-6) receptors, a key signaling pathway in the inflammatory process associated with NMOSD. By targeting IL-6, Yesintek™ helps reduce the risk of relapses that can lead to serious, lasting neurological damage.
How Yesintek™ Works:
- Inhibits IL-6 receptors to limit immune-driven inflammation in the central nervous system
- Helps prevent relapses of NMOSD, which may cause vision impairment, paralysis, or mobility issues
- Aims to preserve neurological function by reducing disease activity over time
- Can be used as a standalone treatment or alongside other immunosuppressants, depending on clinical recommendations
FDA Approval:
2020 – Approved for the treatment of anti-AQP4 antibody-positive NMOSD in adult patients.
For more information, speak with your healthcare provider or visit the official Yesintek™ patient website to learn if Yesintek™ is appropriate for your treatment plan.
Referral Form: |
WHAT IT TREATS: |
MANUFACTURER: Sandoz Inc. |
CLASS: Monoclonal Antibody (mAb)
Interleukin Inhibitor - Specifically: IL-12 and IL-23 antagonist |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: Subcutaneous Injection |
|
FREQUENCY: Initially once every 2 weeks for the first 3 doses. Then, once injection every 4 weeks.
|
Length of infusion: About 30 mins |
FOR MORE INFORMATION: |
Related drugs
